A Pilot Randomized Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase(PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer.

Trial Profile

A Pilot Randomized Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase(PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2013

At a glance

  • Drugs PTVG-HP DNA vaccine (Primary) ; Granulocyte-macrophage colony-stimulating factors
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Apr 2013 Planned end date changed from 1 Mar 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.
    • 16 Feb 2013 Results presented at the 2013 Genitourinary Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top